Group 1: AI in Pharmaceuticals - The application of artificial intelligence (AI) in the pharmaceutical sector has progressed beyond early trials to a systematic deployment phase aimed at creating core value [1] - The focus of competition is shifting from mere technical algorithms to how companies can restructure their data, processes, and organizational systems around key R&D and commercialization aspects [1] - Leading institutions are developing specialized AI systems embedded with compliance frameworks to optimize clinical trial management, enhance laboratory efficiency, and improve the timeliness of business decisions [1] Group 2: Small Nucleic Acid Drugs - The small nucleic acid drug industry is expanding its value narrative from breakthroughs in cardiovascular diseases to new areas such as kidney diseases, which is a key growth story for the sector [2] - The core driver of this trend is the anticipated readout of several key clinical data points in 2026, with therapies targeting important pathway targets showing significant potential to reduce proteinuria and stabilize kidney function [2] - The active clinical advancements by international leading companies provide strong concept validation for the entire sector, expected to drive a new wave of R&D focus and commercial collaborations [2] Group 3: JPMorgan Healthcare Conference - The JPMorgan Healthcare Conference serves as a strategic barometer for observing annual trends, gathering hundreds of global biopharmaceutical companies and investment institutions [3] - The participation and visibility of Chinese companies have significantly increased, showcasing China's advancing position in global pharmaceutical innovation [3] - Key topics at the conference revolve around capital allocation and strategic partnerships, with Chinese assets that possess "innovation upgrades" and "cost advantages" attracting considerable attention [3] Group 4: Market Outlook - The outlook for the innovative drug sector remains strong, with significant capital inflow driven by factors such as robust global competitiveness of Chinese innovations and ongoing domestic policy support for innovative drugs and commercial insurance [3] - The commercial profitability of leading biotech companies is improving, and the sector is characterized by low valuation advantages [3] - The CXO sector is expected to have a positive outlook leading up to 2026, while the medical device sector may see a recovery in the second half of the year, with bright spots in specific segments of medical services [3]

Group 1 - The core viewpoint of the news highlights a strong recovery in the innovative drug sector, with significant stock price increases and positive market sentiment returning to the pharmaceutical industry [1][2] - The Hong Kong pharmaceutical ETF (159718.SZ) has risen by 2.77%, marking a seven-day consecutive increase, driven by strong performances from constituent stocks such as Rongchang Biologics, which rose by 10.56%, and WuXi AppTec, which increased by 7.40% [1] - Rongchang Biologics has entered a substantial licensing agreement with AbbVie for a core dual-antibody product, with an upfront payment of $650 million and potential milestone payments totaling up to $4.95 billion, exceeding expectations [1] Group 2 - WuXi AppTec has announced a revenue forecast for 2025 of 45.456 billion yuan, representing a year-on-year growth of 15.84%, and an adjusted net profit of 14.957 billion yuan, reflecting a 41.33% increase, indicating accelerated performance [1] - Recent market trends show a recovery in the pharmaceutical sector, with emerging hotspots in brain-computer interfaces, small nucleic acid drugs, and AI healthcare, suggesting promising investment opportunities in the industry [1][2] - The innovative drug sector is expected to remain the most important investment theme in the pharmaceutical industry through 2026, with improving market conditions and catalysts expected to drive stock prices [2]

Core Viewpoint - Dongwu Securities initiates coverage on RiboBio (06938) with a "Buy" rating and a target price of HKD 128.3, highlighting its leadership in the domestic small RNA field and the potential of its core product targeting FXI to become a billion-dollar FIC drug [1] Group 1: Company Overview - RiboBio, established in 2007, focuses on siRNA drug development for chronic diseases and possesses globally competitive proprietary GalNac delivery technology [1] - The company has a strategic partnership with Boehringer Ingelheim, potentially earning up to €2.36 billion in milestone payments, enhancing its growth ceiling [1] - RiboBio's RiboGalSTAR technology platform is complemented by RiboOncoSTAR and RiboPepSTAR platforms, positioning the company at the forefront of global small RNA drug development [1] Group 2: Market Potential - The global small RNA drug market is projected to grow from USD 5.7 billion in 2024 to USD 54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [2] - RiboBio, as a leading player in the domestic small RNA sector, is expected to translate its technological barriers into commercial value [2] Group 3: Product Pipeline and Clinical Progress - The FXI siRNA product has the potential to tap into a market space worth billions, addressing the clinical pain points of existing anticoagulant drugs while demonstrating long-lasting effects and safety [3] - The company is advancing its FXI siRNA into Phase 2b clinical trials, following promising Phase 1 results showing strong anticoagulant effects without severe adverse events [3] - RiboBio's pipeline includes several promising candidates targeting various chronic diseases, with significant patient populations and market opportunities [4] - The APOC3 siRNA has entered Phase 2 clinical trials in the EU, while the PCSK9 siRNA has exclusive rights in Greater China, maximizing global value [4] - The HBV siRNA is in Phase 2 global MRCT clinical trials, aiming for functional cure in a market with approximately 280 million infected individuals [4]

Core Viewpoint - Dongwu Securities initiates coverage on RiboBio (06938) with a "Buy" rating and a target price of HKD 128.3, highlighting its leadership in the domestic small RNA field and the potential of its core product targeting FXI to become a billion-dollar FIC drug [1] Group 1: Company Overview - RiboBio, established in 2007, focuses on siRNA drug development for chronic diseases and possesses globally competitive proprietary GalNac delivery technology [1] - The company has a strategic partnership with Boehringer Ingelheim, potentially earning up to €2.36 billion in milestone payments, enhancing its market ceiling [1] - RiboBio's RiboGalSTAR technology platform is complemented by RiboOncoSTAR and RiboPepSTAR, positioning the company at the forefront of global small RNA drug development [1] Group 2: Market Potential - The global small RNA drug market is projected to grow from USD 5.7 billion in 2024 to USD 54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [2] - RiboBio aims to convert its technological barriers into commercial value as a leading player in the domestic small RNA sector [2] Group 3: Product Pipeline and Clinical Progress - The FXI siRNA product has the potential to tap into a market space worth billions, addressing the clinical pain points of existing anticoagulant drugs while demonstrating long-lasting effects and safety [3] - The company is advancing its FXI siRNA into Phase 2 clinical trials, with expectations to initiate Phase 2b trials within the year [3] - RiboBio's pipeline includes several promising candidates targeting various chronic diseases, with significant global patient populations and market opportunities [4] - The APOC3 siRNA has commenced Phase 2 clinical trials in the EU, ranking among the top two globally, while the PCSK9 siRNA has exclusive rights in Greater China [4] - The HBV siRNA is in Phase 2 global MRCT clinical trials, aiming for functional cure, and the company has multiple candidates for IgAN entering clinical stages [4]

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 114.6 RMB / 128.3 HKD, indicating approximately 50% upside potential from the current stock price of 86.8 HKD [1]. Core Insights - The company is a leader in the siRNA field, focusing on chronic diseases and has developed proprietary delivery technologies with global competitiveness. It has established strategic partnerships, including one with Boehringer Ingelheim, which could yield up to 2.36 billion euros in milestone payments [7][19]. - The global market for small nucleic acid drugs is projected to grow significantly, from 5.7 billion USD in 2024 to 54.9 billion USD by 2033, with a CAGR of 21%-29% [7][43]. - The company's FXI siRNA product has the potential to tap into a market space worth over 10 billion USD, addressing significant clinical needs in the anticoagulant drug market [7][43]. Summary by Sections Company Overview - The company, established in 2007, specializes in siRNA drug development and has built a comprehensive industry chain from drug discovery to commercialization, becoming a global leader in the small nucleic acid drug development field [13][14]. Market Potential - The small nucleic acid drug market is expected to grow rapidly, with siRNA drugs projected to capture a larger market share due to advancements in delivery systems and chemical modifications [43][45]. - The report highlights that the siRNA market is anticipated to grow at a higher rate than ASO drugs, with siRNA drugs expected to account for 44.5% of the market by 2024 [43][45]. Product Pipeline - The company has a robust pipeline with four candidates in Phase 2 clinical trials and over 20 projects in preclinical stages, demonstrating a strong capability to advance multiple assets to clinical development each year [26][24]. - Key products include FXI siRNA, APOC3 siRNA, and HBV siRNA, each targeting significant patient populations and addressing unmet clinical needs [7][29]. Financial Projections - Revenue is expected to grow significantly, with total revenue projected to reach 142.63 million RMB in 2024, reflecting a year-on-year increase of 324,052.27% [1]. - The company anticipates achieving profitability by 2030, with a 50% revenue sharing model with partners [7].

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical sector, with the overall performance of the Shenwan Pharmaceutical and Biological Index increasing by 7.8% during the week, outperforming the Shanghai Composite Index which rose by 3.82% [2][3]. Core Insights - The pharmaceutical sector's overall valuation stands at 30.6 times earnings, ranking 10th among 31 Shenwan primary industries [5]. - The report highlights significant developments in the long-term care insurance system transitioning from pilot programs to full establishment during the 14th Five-Year Plan, with coverage reaching nearly 300 million people and fund expenditures exceeding 100 billion yuan by the end of 2025 [11]. - Notable advancements in drug commercialization include the launch of Novo Nordisk's oral GLP-1 weight loss drug Wegovy in the U.S., with monthly costs ranging from $149 to $299 for self-paying patients [13][14]. - Moderna has submitted a New Drug Application (NDA) for its seasonal flu vaccine mRNA-1010, showing promising efficacy results in clinical trials [15]. - Arrowhead has reported positive mid-stage results for its RNAi therapies ARO-INHBE and ARO-ALK7, demonstrating significant reductions in visceral and liver fat [16][17]. - GSK's hepatitis B drug Bepirovirsen has shown statistically significant functional cure rates in its Phase III trials [18]. - Recent approvals for innovative drugs in China include BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which addresses familial chylomicronemia syndrome [19][21]. Summary by Sections Market Performance - The Shenwan Pharmaceutical and Biological Index increased by 7.8%, ranking 6th among 31 Shenwan primary industries [2][3]. - Various sub-sectors showed positive growth, with medical devices and medical outsourcing leading with increases of 10.8% and 11.1%, respectively [5]. Industry Dynamics - The long-term care insurance system is set to expand significantly, with a focus on providing care for the elderly and disabled [11][12]. - The report emphasizes the importance of innovation in drug development, particularly in RNAi therapies and small nucleic acid drugs, which are gaining traction in clinical settings [16][18]. Company Developments - Significant partnerships and collaborations are highlighted, such as the $8.88 billion research collaboration between Insilico Medicine and Servier focusing on oncology [20]. - The report notes the successful commercialization of several new drugs, including BeiGene's and Sanofi's recent approvals, which are expected to impact market dynamics positively [19][21]. - The establishment of new companies and subsidiaries, such as the brain-computer interface subsidiary by Xinwei Medical, indicates a strategic shift towards innovative technologies in healthcare [22].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights the potential of small nucleic acid drugs in weight loss applications, validated by Arrowhead Pharmaceuticals' recent data on INHBE and ALK7 targeted siRNA drugs [3][28] - The new drug sector has shown significant price movements, with notable gains from companies like Frontline Bio (+55.96%) and Shengnuo Pharma (+27.25%) during the week of January 5 to January 11, 2026 [1][16] - There are multiple catalysts expected in the sector, including academic conferences and data releases, which could drive further interest in specific companies [2] Weekly New Drug Market Review - From January 5 to January 11, 2026, the top five gainers in the new drug sector were Frontline Bio (+55.96%), Shengnuo Pharma (+27.25%), Rongchang Bio (+24.64%), Yifang Bio (+22.61%), and Zhixiang Jintai (+19.09%) [1][16] - The top five decliners included Jiahe Bio (-10.69%), Junsheng Tai (-10.56%), Beihai Kangcheng (-5.51%), Yongtai Bio (-3.15%), and Laikai Pharma (-1.84%) [1][16] Weekly Focus on Recommended Stocks - Companies with high overseas growth potential certified by MNCs include Sanofi Pharma, Lianbang Pharma, and Kelun Biotech [2] - Companies with overseas data catalysts include Betta Pharma, Hutchison China MediTech, and Yingen Bio [2] - Potential heavyweights for overseas licensing include Fuhong Hanlin, CSPC Pharmaceutical Group, and Yifang Bio [2] - New innovative drug technology breakthroughs are expected in areas such as small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2] New Drug Industry Key Analysis - Arrowhead Pharmaceuticals has disclosed early weight loss data for its INHBE-targeted siRNA drug, further validating the application potential of small nucleic acid drugs in weight loss [3][28] - Domestic companies are actively developing INHBE-targeted siRNA drugs, including major players like Dairui Bio, Shengyin Bio, and Bowe Pharmaceutical [3][34] - The ALK7-targeted siRNA drug ARO-ALK7 has shown promising results, with a significant reduction in visceral fat observed in clinical trials [40][41] New Drug Approval and Acceptance Status - This week, 8 new drug or new indication applications were approved in China, while 20 applications were accepted [4][43] - The approved drugs include various formulations and indications, such as the injection of human thyroid-stimulating hormone beta and the injection of relaflufin alpha [44] New Drug Clinical Application Approval and Acceptance Status - A total of 47 new drug clinical applications were approved this week, with 46 applications accepted [10][48]

Group 1: Overseas Social Services - The investment rating for the overseas social services sector is positive, with a focus on Macau's gaming revenue maintaining double-digit growth and record visitor numbers during New Year's [1][4]. - In December, Macau's gross gaming revenue reached 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019. The total gross gaming revenue is expected to grow by 9.1% in 2025 [4]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high. On New Year's Day 2026, the number of visitors reached 188,000, the highest ever for that day [4]. Group 2: Overseas Pharmaceuticals - The investment rating for the overseas pharmaceuticals sector is also positive, with significant developments in drug approvals and clinical trials [2][7]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first and only BCL2 inhibitor approved for MCL in the country [8][9]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points, indicating strong market performance [7]. Group 3: Overseas Education - The investment rating for the overseas education sector is favorable, with a focus on vocational education and training [3][14]. - The education index increased by 2.7%, outperforming the Hang Seng Index by 1.3 percentage points, indicating a positive market trend [14]. - The report suggests focusing on Hong Kong vocational education companies, particularly China Oriental Education, which is expected to see enrollment growth due to strategic adjustments in response to market demand [16].

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) officially listed on the Hong Kong Stock Exchange, attracting significant investor interest due to its solid technology and clear pipeline in the biotech sector [1] Company Overview - Ribo Bio's global offering consisted of 31.61 million shares at an issue price of HKD 57.97 per share, with the first-day opening price at HKD 75, reflecting a 29.38% increase from the issue price [1] - The public offering was oversubscribed over 100 times, and the international offering was 16.7 times oversubscribed, raising over HKD 1.8 billion [1] - The company is recognized as a key player in the small nucleic acid technology and pharmaceutical field in China, attracting participation from notable domestic and international investment institutions [1] Technology and Product Pipeline - Ribo Bio possesses a clinically validated liver-targeting GalNAc delivery technology, RiboGalSTAR™, which enables efficient and specific delivery of siRNA to liver cells [2] - The company has established a robust product pipeline with seven self-developed siRNA candidates in clinical stages, including RBD4059, the first siRNA drug targeting FXI for thrombotic diseases [2][3] - RBD4059 shows potential advantages in reducing bleeding risk while effectively combating thrombosis, with a long-acting profile that may extend dosing intervals to several months [2] Market Potential - The global small nucleic acid drug market is experiencing rapid growth, projected to increase from USD 2.7 billion in 2019 to USD 5.7 billion in 2024, and expected to reach USD 20.6 billion and USD 54.9 billion by 2029 and 2034, respectively [3] - Ribo Bio's pipeline aligns with significant unmet clinical needs, particularly in thrombotic diseases and hypertriglyceridemia, which are prevalent and have substantial patient populations [4] - RBD4059 and RBD5044 are positioned to address limitations of current therapies, with RBD5044 targeting high triglyceride levels showing potential to become a best-in-class therapy [4] Future Outlook - The successful listing on the Hong Kong Stock Exchange marks a new chapter for Ribo Bio, providing capital to support its development [5] - With a solid research foundation, differentiated product pipeline, and clear commercial strategy, Ribo Bio is poised to become an influential player in the global small nucleic acid therapy landscape, offering new treatment hopes for millions of patients worldwide [5]